- Treatment of XF-73 Nasal reduces antibiotic use
- Proposed Cancellation of Admission to Trading
- Exercise of Options and Total Voting Rights
- Efficacy of XF-70 in Fungal Skin Infections
- Result of Annual General Meeting
- 2024 Annual General Meeting and Statement
- Destiny Pharma's XF-73 Nasal Awarded MHRA ILAP
- Posting of Annual Report and Notice of AGM
- Full year results and review of strategic options
- Notice of Full Year Results
More ▼
Key statistics
On Monday, Destiny Pharma PLC (DEST:LSE) closed at 3.50, 75.00% above the 52 week low of 2.00 set on Jul 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.00 |
---|---|
High | 4.39 |
Low | 3.50 |
Bid | 2.50 |
Offer | 4.00 |
Previous close | 4.70 |
Average volume | 1.71m |
---|---|
Shares outstanding | 95.77m |
Free float | 72.28m |
P/E (TTM) | -- |
Market cap | 4.07m GBP |
EPS (TTM) | -0.0624 GBP |
Data delayed at least 20 minutes, as of Jul 22 2024 16:25 BST.
More ▼